Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells

BACKGROUND: Chronic myeloid leukemia (CML) pathogenesis is mainly driven by the oncogenic breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) fusion protein. Since BCR-ABL displays abnormal constitutive tyrosine kinase activity, therapies using tyrosine kinase inhibi...

Full description

Saved in:
Bibliographic Details
Published in:Clin Epigenetics
Main Authors: Lernoux, Manon, Schnekenburger, Michael, Losson, Hélène, Vermeulen, Koen, Hahn, Hyunggu, Gérard, Déborah, Lee, Jin-Young, Mazumder, Aloran, Ahamed, Muneer, Christov, Christo, Kim, Dong-Wook, Dicato, Mario, Bormans, Guy, Han, Byung Woo, Diederich, Marc
Format: Artigo
Language:Inglês
Published: BioMed Central 2020
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7236970/
https://ncbi.nlm.nih.gov/pubmed/32430012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-020-00839-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items